Geode Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $102M | Buy |
2,727,633
+246,870
| +10% | +$9.18M | 0.01% | 1188 |
|
|
2026
Q1 | $90.1M | Buy |
2,480,763
+238,132
| +11% | +$10.6M | 0.01% | 1152 |
|
|
2025
Q4 | $104M | Sell |
2,242,631
-36,199
| -2% | -$1.61M | 0.01% | 1053 |
|
|
2025
Q3 | $94.9M | Buy |
2,278,830
+65,505
| +3% | +$2.09M | 0.01% | 1102 |
|
|
2025
Q2 | $63.7M | Buy |
2,213,325
+22,393
| +1% | +$692K | ﹤0.01% | 1293 |
|
|
2025
Q1 | $73.5M | Buy |
2,190,932
+92,091
| +4% | +$3.44M | 0.01% | 1155 |
|
|
2024
Q4 | $107M | Buy |
2,098,841
+250,708
| +14% | +$14M | 0.01% | 953 |
|
|
2024
Q3 | $94.5M | Buy |
1,848,133
+169,746
| +10% | +$8.75M | 0.01% | 1026 |
|
|
2024
Q2 | $75.2M | Buy |
1,678,387
+276,984
| +20% | +$12.8M | 0.01% | 1100 |
|
|
2024
Q1 | $65.6M | Buy |
1,401,403
+48,731
| +4% | +$1.91M | 0.01% | 1173 |
|
|
2023
Q4 | $48.1M | Buy |
1,352,672
+82,998
| +7% | +$2.55M | 0.01% | 1358 |
|
|
2023
Q3 | $37.8M | Buy |
1,269,674
+282,184
| +29% | +$5.81M | ﹤0.01% | 1411 |
|
|
2023
Q2 | $17.8M | Buy |
987,490
+32,630
| +3% | +$651K | ﹤0.01% | 1931 |
|
|
2023
Q1 | $15.3M | Buy |
954,860
+33,630
| +4% | +$622K | ﹤0.01% | 1977 |
|
|
2022
Q4 | $16.9M | Buy |
921,230
+38,135
| +4% | +$672K | ﹤0.01% | 1885 |
|
|
2022
Q3 | $17.3M | Buy |
883,095
+32,157
| +4% | +$656K | ﹤0.01% | 1842 |
|
|
2022
Q2 | $15.9M | Buy |
850,938
+110,553
| +15% | +$2.21M | ﹤0.01% | 1931 |
|
|
2022
Q1 | $16.3M | Buy |
740,385
+41,647
| +6% | +$843K | ﹤0.01% | 2023 |
|
|
2021
Q4 | $19.9M | Buy |
698,738
+178,741
| +34% | +$4.41M | ﹤0.01% | 1971 |
|
|
2021
Q3 | $10.9M | Buy |
519,997
+11,176
| +2% | +$234K | ﹤0.01% | 2395 |
|
|
2021
Q2 | $9.59M | Buy |
508,821
+131,387
| +35% | +$2.31M | ﹤0.01% | 2485 |
|
|
2021
Q1 | $5.77M | Buy |
377,434
+55,933
| +17% | +$867K | ﹤0.01% | 2720 |
|
|
2020
Q4 | $4.54M | Buy |
321,501
+9,724
| +3% | +$135K | ﹤0.01% | 2654 |
|
|
2020
Q3 | $4.88M | Sell |
311,777
-4,783
| -2% | -$73.1K | ﹤0.01% | 2410 |
|
|
2020
Q2 | $5.54M | Buy |
316,560
+182,541
| +136% | +$3.11M | ﹤0.01% | 2283 |
|
|
2020
Q1 | $1.97M | Buy |
134,019
+5,610
| +4% | +$115K | ﹤0.01% | 2681 |
|
|
2019
Q4 | $3.22M | Buy |
128,409
+6,731
| +6% | +$128K | ﹤0.01% | 2725 |
|
|
2019
Q3 | $1.83M | Buy |
121,678
+2,143
| +2% | +$41.7K | ﹤0.01% | 2990 |
|
|
2019
Q2 | $2.99M | Buy |
119,535
+29,343
| +33% | +$727K | ﹤0.01% | 2697 |
|
|
2019
Q1 | $2.05M | Buy |
90,192
+14,539
| +19% | +$357K | ﹤0.01% | 2832 |
|
|
2018
Q4 | $2.27M | Buy |
75,653
+15,538
| +26% | +$437K | ﹤0.01% | 2708 |
|
|
2018
Q3 | $1.72M | Buy |
+60,115
| New | +$1.78M | ﹤0.01% | 2971 |
|
Other funds holding CRNX
FCM
DCM
JTL
BG
BBA
Geode Capital Management's CRNX Position: Q2 2026 in Review
Geode Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 10% in Q2 2026, buying an estimated $9.18M and bringing the position to 2,727,633 shares worth $102M. The position accounts for 0.01% of the portfolio, ranked #1188.
Geode Capital Management first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $107M in Q4 2024. 250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Geode Capital Management held 2,727,633 shares of Crinetics Pharmaceuticals worth $102M as of Q2 2026.
- Geode Capital Management bought 246,870 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $9.18M.
- Crinetics Pharmaceuticals made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1188 holding.
- Geode Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Geode Capital Management's Crinetics Pharmaceuticals position peaked at $107M in Q4 2024.
- 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.